Certificate of Free Sale and Consular Legalisation for Iran Registration

1. Key takeaways

The document chain of an Iranian registration starts with the Certificate of Free Sale (CFS) and its consular legalisation. GRZAN’s assessment is that this is the link in the whole chain that is most easily underestimated and most easily redone in full because of a sequencing error. The correct order is: issuance → notarisation → authentication by the Ministry of Foreign Affairs of China or an authorised body → legalisation by the Iranian embassy or consulate in China. If any step falls out of sequence, the document is voided and the process restarts; and one restart usually takes longer than the preparation of all other materials combined. The reason the sequence is so brittle is that each authority authenticates only the signature and seal of the immediately preceding authority, so a certificate that skips a stage has an unauthenticated gap that no later office can cure. Planning the CFS chain is therefore not a clerical task but a scheduling decision of the first order: it must be sequenced against the readiness of every other document in the dossier, launched neither too early nor too late, and staffed by someone who understands that the four steps cannot be run in parallel or compressed into fewer stages than the chain allows. The chain also consumes calendar time in a way that surprises teams accustomed to electronic attestations: each step is handled by a physical office with its own queue, and none of the four steps can be accelerated by preparing the next document in advance, because each step operates on the output of the previous one. The only lever the project holds is the start date, which is why the backward schedule is the central planning tool for this link.

2. Legal basis

1. The Law Concerning the Regulations on Medical, Pharmaceutical and Food and Beverage Affairs, FAOLEX LEX-FAOC227692, 1955-06-20, Article 3 (import requires the prior approval of the Ministry of Health).
2. CFS and consular legalisation requirements: the manufacturer must provide proof of lawful market status in the country of origin or the principal market, legalised by an Iranian embassy or consulate abroad — as described in public industry material on Iranian submission conditions; no official Iranian document number has been published through open channels, so this is a practical estimate. Because the requirement is described in public guidance rather than in a numbered instrument, the version in force at the time of the submission should be archived with the dossier.
3. Persian translations must be completed and notarised by an Iranian officially recognised body — as above, a practical estimate.

3. Expert insights

Insight one: the “market choice” for the CFS has strategic room. A CFS may come from the manufacturer’s home country or from the principal market. For Chinese manufacturers, where a CE or FDA approval is already held, the choice of which market issues the CFS shapes the reviewer’s first impression of the file. GRZAN recommends preferring the market source that carries the greater review weight and stating the reason for the choice in the dossier. The stated reason costs one paragraph; it converts a question the reviewer might otherwise raise into a decision the company has visibly already made. The choice should be made once, documented, and not revisited unless the underlying approvals change, since inconsistency between the CFS and the rest of the file raises more questions than either choice alone.

Insight two: validity periods are the invisible killer. CFS documents and consular legalisations usually carry a validity period, or a default limit of the form “within a number of months of issuance”. A company that handles them too early in the preparation phase finds them expired at the point of submission. The correct practice is to bring all other materials to 90 percent readiness first, and only then start the CFS and legalisation chain. Working backwards from the submission date, with the CFS as the last document launched, keeps the newest document in the file also the one with the longest remaining life. Validity periods also differ by issuing authority, so the project should confirm the specific limit of its own document rather than relying on a general figure heard from another project.

Insight three: translation and legalisation cannot be merged. The Persian translation must be completed and notarised by an Iranian recognised body, and this runs as a separate chain from consular legalisation. Treating the certification of the translation and the certification of the original as one and the same leads to the entire document set being returned. The two chains serve different readers — one certifies the document to the Iranian state, the other certifies the accuracy of the language to the Iranian user — and each must be planned with its own timeline and its own responsible party. Running the two chains in parallel, each on its own track, is what keeps the combined timeline within the submission window.

4. Practical recommendations

1. Start on a backward schedule: launch the CFS and consular legalisation only after the dossier reaches 90 percent readiness, so the documents do not expire before submission.
2. Fix the sequence: issuance → notarisation → foreign affairs authentication → Iranian embassy or consulate legalisation, written into a standing operating procedure with an audit trail at every step and a named owner for each of the four stages.
3. Schedule translation independently: advance the Persian translation and notarisation in parallel with the legalisation chain, with an Iranian recognised body named as the issuing party.
4. Reserve a redo margin: keep time and budget for 1 complete redo of the chain in the project plan, so a sequencing failure is an expense rather than a crisis.

5. Verification checklist

• □ The issuing market for the CFS has been determined and the reason for the choice recorded in writing
• □ The legalisation chain order has been fixed into a standard operating procedure with a step-by-step audit trail
• □ The Persian translation was completed by an Iranian recognised body and has been notarised
• □ The CFS and legalisation were started only after 90 percent dossier readiness, avoiding the validity-period trap
• □ A full redo cycle and budget have been reserved for one complete rerun of the chain

Regulatory information verified as of October 29, 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Iranian market. Our team manages IFDA (Iran FDA) registration procedures, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com